Overview

A Placebo-Controlled Phase 3 Trial of Repeated Lamazym Treatment of Subjects With Alpha-Mannosidosis

Status:
Completed
Trial end date:
2014-05-01
Target enrollment:
Participant gender:
Summary
The overall objective of this trial is to evaluate the efficacy and safety of repeated Lamazym i.v. treatment, compared with placebo, in subjects 5-35 years of age with alpha-Mannosidosis
Phase:
Phase 3
Details
Lead Sponsor:
Zymenex A/S
Collaborator:
European Commission